The share price has lost more than 20% within the last three years due to management changes/failures and concerns over 2031 patent cliff of its blockbuster drug, Dupixent, which is the fourth biggest-selling drug in the world, and accounts for around 36% of Sanofi's revenue.
~12 trailing PE ratio, 9 forward PE, 1.2 P/B, 2.2 EV/sales, expected to grow EPS by 10% in 2026 and 6.5% in 2027. Revenue growth is expected at mid to high single-digit
New CEO Belén Garijo started May 2026, to cleanup the mess of previous pipeline failures. Which is exactly what she has achieved in her former company Merck KgAa.
It is arguably cheap given the known patent cliff and execution risks are already priced in. 2031 is 5 years away for them to either create a new blockbuster or M&A, while Dupixent sales still expected to grow 8-9% in the meantime. And you get paid 5.6% dividend while you wait.
I don't see a lot of mention of Sanofi, anyone here have looked into the company?